Jennifer Ang Chan MD
Hematologic Oncology
Instructor in Medicine, Dana-Farber Cancer Institute
Join to View Full Profile
44 Binney St# DanaBoston, MA 02115
Phone+1 617-632-6315
Fax+1 617-632-5370
Dr. Chan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000
Certifications & Licensure
MA State Medical License 2003 - 2026
NH State Medical License 2023 - 2025
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer Start of enrollment: 2005 Jul 01
- RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Start of enrollment: 2008 May 01
- Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Start of enrollment: 2008 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Burden of Comorbidities and Concomitant Medications and Their Associated Costs in Patients with Gastroenteropancreatic or Lung Neuroendocrine Tumors: Analysis of US Ad...Jennifer A Chan, Antonio Ribeiro-Oliveira Jr, Aude Houchard, Syvart Dennen, Yutong Liu
Advances in Therapy. 2025-03-13 - 10 citationsPhase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.Jennifer A Chan, Susan Geyer, Tyler Zemla, Michael V Knopp, Spencer Behr
The New England Journal of Medicine. 2025-02-13 - A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.Kimberly Perez, Matthew H Kulke, Hui Zheng, Jill Allen, Jeffrey Clark
The Oncologist. 2025-01-17
Other
- Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growthChan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-optio
UpToDate, Wolters Kluwer Health - 2013-04-15 - Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoringChan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-presentatio
UpToDate, Wolters Kluwer Health - 2012-07-05 - Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretionChan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-systemic-th
UpToDate, Wolters Kluwer Health - 2013-02-05
Press Mentions
FDA Approves Cabozantinib for Previously Treated Advanced Neuroendocrine TumorsMarch 31st, 2025- FDA Grants Approval for Innovative Dual-Action Therapy Targeting Previously Treated Advanced Neuroendocrine Tumors, Supported by Dana-Farber ResearchMarch 26th, 2025
- FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber ResearchMarch 26th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
